Prostate-specific antigen doubling time as a prognostic marker in prostate cancer

Nature Clinical Practice Urology

Volumn 2, Issue 10, 2005, Pages 482-491

  Eastham, James A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostate specific antigen doubling time; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; BEAM THERAPY; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COMPUTER PROGRAM; CONSERVATIVE TREATMENT; DISEASE COURSE; FLOW KINETICS; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIFESPAN; MALE; MATHEMATICAL MODEL; METASTASIS POTENTIAL; POSTOPERATIVE CARE; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SEMINAL VESICLE; STATISTICAL MODEL; SURVIVAL RATE; TIME; TIME SERIES ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH;

ALGORITHMS; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 27744555986     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0321     Document Type: Review

References (26)

1. Kattan MW et al. (2003) Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170: 1792-1797
2. Partin AW et al. (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445-1451
3. Kattan MW et al. (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771
4. Kattan MW et al. (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352-3359
5. Kattan MW et al. (2001) Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58:393-399
6. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597
7. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383
8. Memorial Sloan-Kettering Cancer Center predication tools [http://www.mskcc.org/predictiontools]
9. Epstein JI et al. (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407-2411
10. Choo R et al. (2002) Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167: 1664-1669
11. Klotz L (2005) Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Europ Urol 47: 16-21
12. Egawa S et al. (2000) Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3: 269-274
13. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041
14. D'Amico AV et al. (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95: 281-286
15. Stephenson AJ et al. (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291: 1325-1332
16. Ward JF et al. (2004) Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172: 2244-2248
17. D'Amico AV et al. (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573
18. D'Amico AV and Hanks GE (1993) Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72: 2638-2643
19. Zelefsky MJ et al. (2005) Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 23: 826-831
20. Pollack A et al. (1994) Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74: 670-678
21. Ward JF et al. (2003) The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170: 1872-1876
22. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383
23. D'Amico AV et al. (2004) Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172: S42-S46
24. Roberts SG et al. (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76: 576-581
25. Rabbani F et al. (1999) Prostate specific antigen doubling time after radical prostatectomy: Effect of neoadjuvant androgen deprivation therapy. J Urol 161: 847-852
26. Trapasso JG et al. (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: 1821-1825